Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Journal of Complementary and Integrative Medicine

Editor-in-Chief: Lui, Edmund

Hrsg. v. Ko, Robert / Leung, Kelvin Sze-Yin / Saunders, Paul / Suntres, PH. D., Zacharias


CiteScore 2018: 1.26

SCImago Journal Rank (SJR) 2018: 0.327
Source Normalized Impact per Paper (SNIP) 2018: 0.575

Online
ISSN
1553-3840
Alle Formate und Preise
Weitere Optionen …

The use of an anti-inflammatory supplement in patients with chronic kidney disease

Jennifer J. Moreillon / Rodney G. Bowden / Erika Deike / Jackson Griggs / Ron Wilson / Brian Shelmadine / Matt Cooke / Alexander Beaujean
Online erschienen: 01.07.2013 | DOI: https://doi.org/10.1515/jcim-2012-0011

Abstract

Chronic kidney disease (CKD) is characterized by a continuous reduction in kidney function, increased inflammation, and reduced antioxidant capacity. The objective of this study was to assess the effects of a herbal supplement on systemic inflammation and antioxidant status in non-dialysis CKD patients. Sixteen patients with CKD (56.0±16.0 yrs, 171.4±11.9 cm, 99.3±20.2 kg) were randomly chosen to receive a herbal supplement composed of Curcuma longa and Boswellia serrata, or placebo. Plasma levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), glutathione peroxidase (GPx), and serum C-reactive protein (CRP) were measured at baseline and 8 weeks. Baseline data demonstrated elevated inflammation and low antioxidant levels. A significant time effect (p=0.03) and time x compliance interaction effect (p=0.04) were observed for IL-6. No significant differences were observed for any other variables. This study demonstrates that mild and moderate CKD is associated with chronic inflammation and low antioxidant activity. Systemic inflammation and impaired antioxidant status may be greater in CKD populations with multiple comorbidities. Curcumin and Boswellia serrata are safe and tolerable and helped to improve the levels of an inflammatory cytokine.

Keywords: chronic kidney disease,; curcumin,; Boswellia serrata,; alternative medicine

References

  • 1.

    Centers for Disease Control and Prevention. National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the united states, 2010. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, 2010.Google Scholar

  • 2.

    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76–9.Google Scholar

  • 3.

    Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. JMCP 2007;13(3 Suppl):S1–S9.Google Scholar

  • 4.

    Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin–a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008;44(3):323–327. doi:10.1016/j.cyto.2008.08.014CrossrefGoogle Scholar

  • 5.

    Oner-Iyidogan Y, Oner P, Kocak H, Gurdol F, Bekpinar S, Unlucerci Y, et al. Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin Exp Med 2009. doi:10.1007/s10238–009–0035–3CrossrefGoogle Scholar

  • 6.

    Pawlak K, Mysliwiec M, Pawlak D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine 2008;43(1):98–101. doi:10.1016/j.cyto.2008.03.011CrossrefGoogle Scholar

  • 7.

    Rastmanesh MM, Bluyssen HA, Joles JA, Boer P, Willekes N, Braam B. Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. Eur J Pharmacol 2008;593(1–3):99–104. doi:10.1016/j.ejphar.2008.07.013CrossrefGoogle Scholar

  • 8.

    Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21(6):845–53.Google Scholar

  • 9.

    El-Far MA, Bakr MA, Farahat SE, Abd El-Fattah EA. Glutathione peroxidase activity in patients with renal disorders. Clin Exp Nephrol 2005;9(2):127–31. doi:10.1007/s10157–005–0343–1CrossrefPubMedGoogle Scholar

  • 10.

    Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Trans Res 2009;153(2):77–85. doi:10.1016/j.trsl.2008.11.007CrossrefGoogle Scholar

  • 11.

    Zachara BA, Koterska D, Manitius J, Sadowski L, Dziedziczko A, Salak A, et al. Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. Biol Trace Elem Res 2004;97(1):15–30. doi:10.1385/BTER:97:1:15CrossrefGoogle Scholar

  • 12.

    Batista Junior ML, Lopes RD, Seelaender MC, Lopes AC. Anti-inflammatory effect of physical training in heart failure: role of TNF-alpha and IL-10. Arq Bras Cardiol 2009;93(6):643–51, 692–700.Google Scholar

  • 13.

    Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fito M, Escoda R, et al. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the mediterranean diet. Am J Clin Nutr 2009;89(1):248–56. doi:10.3945/ajcn.2008.26094CrossrefGoogle Scholar

  • 14.

    Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006;17(12 Suppl 3):S231–S235. doi:10.1681/ASN.2006080938CrossrefGoogle Scholar

  • 15.

    Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergstrom J, Palmblad J, et al. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999;246(5):503–7.Google Scholar

  • 16.

    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the united states, 1990–1997: results of a follow-up national survey. JAMA 1998;280(18):1569–75.Google Scholar

  • 17.

    Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United states, 2002. Adv Data 2004;343(343):1–19.Google Scholar

  • 18.

    Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65(11):1631–1652. doi:10.1007/s00018–008–7452–4CrossrefGoogle Scholar

  • 19.

    Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73(2):399–409. doi:10.1124/mol.107.039818CrossrefGoogle Scholar

  • 20.

    Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 2007;55(25):10150–5. doi:10.1021/jf0723965CrossrefGoogle Scholar

  • 21.

    Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007;1770(6):989–96. doi:10.1016/j.bbagen.2007.02.004CrossrefGoogle Scholar

  • 22.

    Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, Sica DA, et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: the role of inflammation. Am J Physiol Ren Physiol 2009. doi:10.1152/ajprenal.90732.2008CrossrefGoogle Scholar

  • 23.

    Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs RD 2008;9(4):243–50.CrossrefGoogle Scholar

  • 24.

    Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, et al. Effects of boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2(1):37–43.Google Scholar

  • 25.

    Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67(5):391–95.Google Scholar

  • 26.

    Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007;22(12):1445–51. doi:10.1007/s00384–007–0364–1CrossrefGoogle Scholar

  • 27.

    Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008;10(4):R85. doi:10.1186/ar2461Google Scholar

  • 28.

    Bayrak O, Uz E, Bayrak R, Turgut F, Atmaca AF, Sahin S, et al. Curcumin protects against ischemia/reperfusion injury in rat kidneys. World J Urol 2008;26(3):285–91. doi:10.1007/s00345–008–0253–4CrossrefGoogle Scholar

  • 29.

    Rafiee P, Nelson VM, Manley S, Wellner M, Floer M, Binion DG, et al. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2009;296(2):G388–G398. doi:10.1152/ajpgi.90428.2008Google Scholar

  • 30.

    Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 2005;135(5):1093–101.Google Scholar

  • 31.

    Lee JY, Greene PG, Douglas M, Grim C, Kirk KA, Kusek JW, et al. Appointment attendance, pill counts, and achievement of goal blood pressure in the African American study of kidney disease and hypertension pilot study. Control Clin Trials 1996;17(4 Suppl):34S-39S.CrossrefGoogle Scholar

  • 32.

    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–S266.Google Scholar

  • 33.

    Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995;49(11):1551–6.CrossrefGoogle Scholar

  • 34.

    Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee – a randomized double blind placebo controlled trial. Phytomed Int J Phytotherap Phytopharmacol 2003;10(1):3–7.CrossrefGoogle Scholar

  • 35.

    Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol 2008;28(2):272–277. doi:10.1161/ATVBAHA.107.155606CrossrefGoogle Scholar

  • 36.

    Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS, Balakrishnan A. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFalpha, IL-1beta, NO and MAP kinases. Int Immunopharmacol 2007;7(4):473–82. doi:10.1016/j.intimp.2006.12.003CrossrefGoogle Scholar

  • 37.

    Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004;19(10):2505–12. doi:10.1093/ndt/gfh207CrossrefGoogle Scholar

  • 38.

    Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003;25(2):213–24.CrossrefGoogle Scholar

  • 39.

    Sander O, Herborn G, Rau R. Is H15 (resin extract of Boswellia serrata, “incense”) a useful supplement to established drug therapy of chronic polyarthritis? results of a double-blind pilot study. [Ist H15 (Harzextrakt von Boswellia serrata, “Weihrauch”) eine sinnvolle Erganzung zur etablierten medikamentosen Therapie der chronischen Polyarthritis?–Ergebnisse einer doppelblinden Pilotstudie]. Z Rheumatol 1998;57(1):11–6.Google Scholar

  • 40.

    Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265(3):621–36.Google Scholar

  • 41.

    Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000;148(2):209–14.Google Scholar

  • 42.

    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997;336(14):973–9. doi:10.1056/NEJM199704033361401CrossrefGoogle Scholar

  • 43.

    Naesh O. Back to the future: postoperative pain management beyond COX-2 inhibitors. N Z Med J 2006;119(1242):U2170.Google Scholar

  • 44.

    Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, et al. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994;266(2 Pt 1):C367–C375.Google Scholar

  • 45.

    Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129(2):231–4. doi:10.1038/sj.bjp.0703067CrossrefGoogle Scholar

  • 46.

    Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000;85(3):1334–9.CrossrefGoogle Scholar

  • 47.

    Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 2005;67(4):1216–33. doi:10.1111/j.1523–1755. 2005.00200.xCrossrefGoogle Scholar

  • 48.

    Richard MJ, Arnaud J, Jurkovitz C, Hachache T, Meftahi H, Laporte F, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991;57(1):10–5.CrossrefGoogle Scholar

  • 49.

    Hill KE, Burk RF, Lane JM. Effect of selenium depletion and repletion on plasma glutathione and glutathione-dependent enzymes in the rat. J Nutr 1987;117(1):99–104.Google Scholar

  • 50.

    Cohen HJ, Chovaniec ME, Mistretta D, Baker SS. Selenium repletion and glutathione peroxidase–differential effects on plasma and red blood cell enzyme activity. Am J Clin Nutr 1985;41(4):735–47.Google Scholar

  • 51.

    Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114(12):1752–61. doi:10.1172/JCI21625CrossrefGoogle Scholar

  • 52.

    Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004;279(41):42351–4. doi:10.1074/jbc.R400019200CrossrefGoogle Scholar

  • 53.

    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003;42(5):1050–65. doi:10.1161/01.HYP.0000102971.85504.7cCrossrefGoogle Scholar

  • 54.

    Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 2001;59(2):407–14. doi:10.1046/j.1523–1755.2001. 059002407.xCrossrefGoogle Scholar

  • 55.

    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Eng J Med 2004;351(13):1296–305. doi:10.1056/NEJMoa041031CrossrefGoogle Scholar

  • 56.

    Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54(1):236–44. doi:10.1046/j.1523–1755.1998.00981.xCrossrefGoogle Scholar

  • 57.

    Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17(9):1684–8.Google Scholar

  • 58.

    Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16(Suppl 1):S83–S88.CrossrefGoogle Scholar

Artikelinformationen

Erhalten: 07.09.2011

Angenommen: 17.05.2012

Online erschienen: 01.07.2013


Quellenangabe: Journal of Complementary and Integrative Medicine, Band 10, Heft 1, Seiten 143–152, ISSN (Online) 1553-3840, ISSN (Print) 2194-6329, DOI: https://doi.org/10.1515/jcim-2012-0011.

Zitat exportieren

©2013 by Walter de Gruyter Berlin / Boston.Get Permission

Zitierende Artikel

Hier finden Sie eine Übersicht über alle Crossref-gelisteten Publikationen, in denen dieser Artikel zitiert wird. Um automatisch über neue Zitierungen dieses Artikels informiert zu werden, aktivieren Sie einfach oben auf dieser Seite den „E-Mail-Alert: Neu zitiert“.

[1]
EntsarA Saad, HussamA El-Gayar, RedaS El-Demerdash, and KholoudH Radwan
Pharmacognosy Magazine, 2018, Jahrgang 14, Nummer 58, Seite 634
[2]
Ajaikumar B. Kunnumakkara, Choudhary Harsha, Kishore Banik, Rajesh Vikkurthi, Bethsebie L. Sailo, Devivasha Bordoloi, Subash C. Gupta, and Bharat B. Aggarwal
Expert Opinion on Drug Metabolism & Toxicology, 2019, Seite 1
[3]
Atefeh Hosseini, Taher Nejadsattari, and Mohsen Zargar
Archives of Clinical Infectious Diseases, 2019, Jahrgang 14, Nummer 4
[4]
Kolsoum Rezaie Kahkhaie, Ali Mirhosseini, Ali Aliabadi, Asadollah Mohammadi, Mohammad Javad Mousavi, Saeed Mohammadian Haftcheshmeh, Thozhukat Sathyapalan, and Amirhossein Sahebkar
Inflammopharmacology, 2019
[5]
Reza Tabrizi, Sina Vakili, Maryam Akbari, Naghmeh Mirhosseini, Kamran B. Lankarani, Maryam Rahimi, Moein Mobini, Sadegh Jafarnejad, Zahra Vahedpoor, and Zatollah Asemi
Phytotherapy Research, 2018
[6]
Enzo R. Russo, Inalda Facincani, Katia C. Nakazato, Terezila M. Coimbra, Eduardo J. Crevelin, Ana Maria S. Pereira, and Fabio Carmona
Phytotherapy Research, 2018
[7]
Ajaikumar B. Kunnumakkara, Kishore Banik, Devivasha Bordoloi, Choudhary Harsha, Bethsebie L. Sailo, Ganesan Padmavathi, Nand K. Roy, Subash C. Gupta, and Bharat B. Aggarwal
Frontiers in Pharmacology, 2018, Jahrgang 9
[8]
Livia de Almeida Alvarenga, Viviane de Oliveira Leal, Natália Alvarenga Borges, Aline Silva de Aguiar, Gerd Faxén-Irving, Peter Stenvinkel, Bengt Lindholm, and Denise Mafra
Journal of Functional Foods, 2018, Jahrgang 40, Seite 715
[9]
Ying Hu, Lijun Mou, Fuye Yang, Haiyan Tu, and Wanbing Lin
Molecular Medicine Reports, 2016, Jahrgang 14, Nummer 4, Seite 3229
[10]
Konstantina P. Poulianiti, Antonia Kaltsatou, Georgia I. Mitrou, Athanasios Z. Jamurtas, Yiannis Koutedakis, Maria Maridaki, Ioannis Stefanidis, Giorgos K. Sakkas, and Christina Karatzaferi
Oxidative Medicine and Cellular Longevity, 2016, Jahrgang 2016, Seite 1
[11]
Siddhartha Ghosh, Todd Gehr, and Shobha Ghosh
Molecules, 2014, Jahrgang 19, Nummer 12, Seite 20139
[12]
Liyu He, Xiaofei Peng, Jiefu Zhu, Guoyong Liu, Xian Chen, Chengyuan Tang, Hong Liu, Fuyou Liu, and Youming Peng
Canadian Journal of Physiology and Pharmacology, 2015, Jahrgang 93, Nummer 4, Seite 275

Kommentare (0)